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Patients with a diagnosis of cancer are purported to have poor outcomes from COVID-19. However, cancer is a 51 
heterogeneous group of diseases encompassing a spectrum of tumour subtypes. The aim of this study is to 52 
evaluate COVID-19 risk according to tumour subtype and patient demographics in the cancer population. 53 
 54 
Methods 55 
A comparison of adult cancer patients enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) from 56 
18th March to 8th May and a parallel non-COVID-19 UK cancer control population cohort was performed, analysing 57 
effect of tumour subtype and patient demographics (age and sex) on the incidence and mortality from COVID-19 58 
using univariate and multivariable models. 59 
   60 
Findings 61 
In 1,044 patients with COVID-19, an overall case fatality rate of 0.31 was observed, of which 92.5% (295/319) of 62 
deaths due to COVID-19. Age is a risk factor for COVID-19 with a case fatality rate (CFR) in the 40-49, 50-59, 60-63 
69, 70-79 and over 80 groups being 0.10, 0.17, 0.28, 0.35 and 0.48 respectively. Patients with haematological 64 
malignancies (leukaemia/lymphoma/myeloma) run a more severe COVID-19 trajectory (OR 1.57, 95% CI 1.15-65 
2.15; p<0.01) compared to patients with solid organ tumours.  CFR following COVID-19 in patients with leukaemia 66 
is increased compared to other cancer types, even considering other risk factors (OR 2.25, 95% CI [1.13 to 4.57]; 67 
p=0.02). Recent chemotherapy use in haematological patients is associated with additional risk of death on 68 
multivariate analyses (OR 2.09 95% CI [1.09 to 4.08]; p=0.03). 69 
 70 
Interpretation 71 
Cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-19 phenotypes. We 72 
have generated individualised risk tables for cancer patients taking into account age/sex and tumour subtype. This 73 
will be useful for physicians to have an informed risk-benefit discussion to explain COVID-19 risk and to enable an 74 
evidenced approach to national social isolation policies.  75 
 76 
Funding 77 





The disease course of individuals contracting SARS-CoV-2 infection is phenotypically diverse. Many patients suffer 81 
only mild symptoms and it is becoming increasingly apparent from antibody data that others suffer no symptoms 82 
at all but can actively carry and transmit the infection. However, at the other end of the spectrum, some individuals 83 
develop very severe symptoms and can follow an extreme phenotype with the development of respiratory failure, 84 
cytokine release syndrome and multi-organ failure. Subgroups of COVID-19 patients have been identified who 85 
appear to be at increased risk of morbidity and mortality, including patients of advancing age, male gender (versus 86 
female) and those with co-morbidities such as hypertension, chronic lung disease, diabetes and cancer. 1 87 
 88 
Since COVID-19 started to spread across the globe in early 2020, patients with a diagnosis of cancer were 89 
designated as a particularly vulnerable subgroup of the population. Cancer patients have been reported to be not 90 
only at increased risk of contracting SARS-CoV-2 infections, but also of running a more severe disease course, 91 
with a large proportion requiring higher levels of intensive care, having a more rapidly evolving disease, and with 92 
increased risk of death. 2 3 4  However, cancer encompasses a myriad of disease, with a diverse array of primary 93 
tumour subtype and stages, affecting a heterogeneous group of patients of all ages, and which result in very 94 
different cancer prognoses and outcomes. Therefore, labelling all cancer patients as ‘COVID-19 vulnerable’ is 95 
probably neither reasonable nor informative.  96 
 97 
As a consequence of generic advice given to ‘COVID-19 clinically vulnerable’ members of the population, cancer 98 
patients (of any age, gender, tumour subtype and stage) have been labelled as high risk from COVID-19 and this 99 
has led to sweeping changes in cancer management for all cancer types over the last few months, including 100 
abbreviation of radiotherapy, switching from IV to oral chemotherapy regimens, and modification in immunotherapy 101 
usage. 5 6 7 8 These changes, perhaps reasonably in an acute pandemic situation, were instigated with very little 102 
evidence to support them. Due to a paucity of evidence, there has been little attempt to define the individualised 103 
risk for a given patient, taking into account their primary tumour subtype, age and gender. 104 
 105 
We report here, from the UK Coronavirus Cancer Monitoring Project 9, the first analysis of the complex interaction 106 
between patient demographics and tumour subtype, to more accurately estimate the risk of SARS-CoV-2 infection 107 
/ COVID-19 in patients with cancer. We describe the clinical outcomes of COVID-19+ cancer patients entered on 108 
the UKCCMP registry, and compare primary cancer subtype prevalence/case fatality rate to the United Kingdom’s 109 





Study Design and Participants 113 
The UK Coronavirus Cancer Monitoring Project (UKCCMP) database of United Kingdom (UK) cancer patients has 114 
been designed as a Public Health Surveillance registry for the COVID-19 pandemic and a prospective 115 
observational cohort study 10. The database was designed as a public health surveillance registry to support rapid 116 
clinical decision making, in accordance with the UK Policy Framework for Health and Social Care Research, the 117 
UK National Research Ethics Service, and the UK Governance Arrangement for Research Ethic Committees.  118 
Ethical approval was not specifically required, as confirmed following consultation with the Health Research 119 
Authority (HRA). The study involved the collection of clinical and outcome data as routinely recommended for good 120 
practice. Each participating centre was required to obtain local approvals and follow local information governance 121 
processes. Written consent was not required for inclusion in this study. Eligibility criteria were (1)  adult patients 122 
(18 and older), (2) with active cancer, (3) who presented to the UKCCMP network from March 18th 2020 to 8th May 123 
2020, (4) with a positive SARS-CoV-2 PCR test were eligible for enrolment on the registry. Patients with active 124 
cancer were defined as those with metastatic cancer or those undergoing anti-cancer treatment in any setting 125 
(curative/radical/adjuvant/neoadjuvant) or those treated within the past 12 months with surgery/systemic anti-126 
cancer therapy/radiotherapy. All patients attended secondary care to be reviewed for potential hospitalization and 127 
were not part of a proactive surveillance program. Management of cancer patients with COVID-19 was directed by 128 
the patient’s clinician team without input from the UKCCMP and were based on local policies and standard UK 129 
clinical practice at the time of this study. Decisions on ITU admission and ventilation were guided by the UK National 130 
Health Service, National Institute of Health and Care Excellence COVID-19 rapid guidelines. 11 This study was 131 
conducted in accordance with the Strengthening the Reporting of Observational studies in Epidemiology 132 
(STROBE) statement.  133 
 134 
Data Collection and analysis 135 
Data collection was performed as previously outlined 10. Tumour subtype and demographics analysis utilised the 136 
latest release of the “Cancer Registration Statistics, England, 2017” 12. This is the latest cancer registration 137 
database in England and involves registrations of patients up to 2017. Cancer registrations in England take years 138 
after a given calendar year to reach nationally validated quality control measures for robustness of analyses due 139 
to continuing accrual of registrations.  140 
 141 
Outcomes 142 
The main outcome of interest was the effect of primary tumour subtype, age and gender, and likelihood of 143 
contracting SARS-CoV-2 infection and subsequent COVID-19 clinical course. A comparison of adult cancer 144 
patients enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) and a parallel non-COVID-19 UK 145 
cancer control population cohort was performed (the UK Office for National Statistics (ONS) cancer control 146 
dataset), analysing effect of tumour subtype and patient demographics (age and sex) on the incidence and mortality 147 
from COVID-19 using univariate fisher exact tests and multivariable logistic regression. The primary outcome of 148 
interest was all-cause inpatient case fatality rate (during the COVID-19 episode). This included death designated 149 
as a direct result of COVID-19 as well as death from any other cause such as cancer progression and treatment 150 
toxicity. Skin cancers were not included in these analyses as the majority are not managed in oncological setting 151 
so they are not representative as a comparison group.  152 
 153 
Statistical analysis & Data visualisation 154 
 155 
This analysis was a pre-planned analysis milestone. Analyses were performed without an a priori power calculation, 156 
as this were not possible due to the lack of information about the effect size/interactions and the nature and rapid 157 
evolution of the pandemic. Patients that had missing data points required for a particular analysis were excluded. 158 
A two-sided Fisher’s exact test was used to compare categorical data from different categories. Multivariable 159 
logistic regression 13 was used to estimate odds ratios and 95% confidence intervals of each defined factor after 160 
adjustment for potential confounders of patient age and gender. Analyses were performed in R version 3.6.3. 161 
 162 
Role of the funding source 163 
 164 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of 165 
the report. LL, JBC, TS, RA, VB, NAC, HMC, AS, SH, CPM, CP, ASO, CDT, CV had access to the raw data. LL, 166 





We are reporting on 1,044 patients with active cancer and a documented SARS-CoV-2 infection/COVID-19 170 
registered in the UKCCMP database from the 18th of March with outcomes censored at 8th May 2020. 87 patients 171 
were excluded from the analysis as they had an unspecified tumour site or malignant neoplasia of the skin. Of this 172 
cohort, 595/1044 were men (57.0%) and the median age was 70 years, IQR 60-77. Patients were followed up from 173 
the point of COVID-19 diagnosis to either discharge from hospital or death. Median follow up was 6 days (IQR 2-174 
11). 175 
 176 
The demographics and cancer subtype of the COVID-19+ cancer population from the UKCCMP registry were 177 
compared with those from the population of cancer patients represented in the ONS cancer census which was 178 
used as a historical control group. Compared to the ONS control population of cancer patients, we found that 179 
COVID-19+ cancer patients were significantly more likely to be male (57.1% (592/1037) in UKCCMP vs 51.3% 180 
(145034/282878) in ONS, OR 1.26 95% CI [1.12 to 1.43]; p<0.01), but the age distribution of cancer patients who 181 
contracted COVID-19 was not significantly different to the ONS cancer control population (median age group 70-182 
79 for both series) (appendix page 2).  183 
 184 
We found that certain tumour subtypes were overrepresented in the UKCCMP COVID-19+ patient cohort compared 185 
with the ONS control population. Patients with haematological malignancies appeared to be at significantly 186 
increased risk, and these included those with leukaemia (OR 2.82 95% CI [2.21 to 3.55]; p<0.01), myeloma (OR 187 
2.03 95% CI [1.42 to 2.83]; p<0.01) and lymphomas (OR 1.63 95% CI [1.28 to 2.06]; p<0.01) (Table 1). In contrast, 188 
patients with lung cancer and prostate cancer were relatively underrepresented in the COVID19+ UKCCMP series 189 
compared to the control ONS series of cancers. Lung cancer made up 10.7% (111/1041) of the UKCCMP series 190 
compared to 13.7% (38878/282878) of ONS cases (OR 0.75 95%CI [0.61-0.91]; p<0.01). Similarly, prostate cancer 191 
comprised 11.0% (114/1041) of the UKCCMP series compared to 14.6% (41200/282878) of the ONS cohort (OR 192 
0.72 95%CI [0.59-0.88]; p<0.01). 193 
 194 
319 of the 1044 COVID-19+ UKCCMP cancer patients died, a case fatality rate (CFR) 0.31, of which the cause of 195 
death was recorded as due to COVID-19 in 92.5% (n=295). The all-cause CFR in cancer patients following COVID-196 
19 was significantly linked to increasing age, with the CFR in the 40-49, 50-59, 60-69, 70-79 and over 80 groups 197 
being 0.10, 0.17, 0.28, 0.35 and 0.48 respectively, and no deaths recorded in the under 40 group (Figure 1, 198 
Appendix page 2-3). In addition, the all-cause CFR in cancer patients once they had contracted COVID-19 was 199 
significantly associated with gender, in males being 0.36 (212/595) and that in females being 0.24 (105/445), (OR 200 
1.92 95% CI [1.51 to 2.45], p<0.01)   201 
 202 
We compared the case fatality rate for each primary tumour subtype in the UKCCMP to a reference, the C15-C26 203 
subtype (digestive organs) as it was the tumour subtype with the central case fatality rate. On univariate analysis 204 
we observed a significantly higher risk in patients with prostate cancer (OR 2.14, 95% CI [1.17 to 3.96]; p=0.01), 205 
and leukaemia (OR 2.03, 95% CI [1.04 to 3.97]; p=0.04) and a significantly lower risk for patients with breast cancer 206 
(OR 0.53, 95% CI [0.28 to 1.00]; p<0.05) and female genital cancers (OR 0.36, 95% CI [0.13-0.87]; p=0.03) (Figure 207 
2, appendix page 3). We then performed a multivariate correction for clinically relevant confounders, age and 208 
gender. Compared to the rest of the UKCCMP cohort, patients with leukaemia remained at significantly increased 209 
case fatality rate (OR 2.25, 95% CI [1.13 to 4.57]; p=0.02),  (Table 2, appendix page 4). After multivariate correction, 210 
prostate cancer was no longer significantly associated with increased case fatality rate, and breast and female 211 
genital cancers were no longer associated with reduced case fatality rate, highlighting the striking effect of patient 212 
age and gender on case fatality rate. Also, on multivariate analysis, we did not find a significantly increased case 213 
fatality rate from COVID-19 in the lung cancer population (OR 1.41 95%CI [0.75-2.67]; p=0.29) compared to the 214 
rest of the UKCCMP population. 215 
 216 
We then undertook a specific detailed analysis of the 227 patients with haematological malignancies who were 217 
diagnosed with COVID-19. Compared to the remainder of the UKCCMP cohort (with non-haematological cancers), 218 
we found that these patients presented with similar symptoms (appendix page 5). Adjusting for potential 219 
confounding variables of age and gender, patients with haematological malignancies were significantly more likely 220 
to require high flow oxygen (OR 1.82 95% CI [1.11 to 2.94]; p =0.015)], non-invasive ventilation (OR 2.10 95% CI 221 
[1.14-3.76; p=0.01]), ITU admission for ventilation (OR 2.73 % CI [1.43 to 5.11]; p<0.01) and have a severe/critical 222 
disease course (OR 1.57 95% CI [1.15 to 2.15]; p<0.01) (appendix page 5). 47.6% (108/227) of patients with 223 
haematological malignancies had received recent chemotherapy within 4 weeks of COVID-19 presentation 224 
(appendix page 5). On univariate analysis, recent use of chemotherapy in haematology patients was not associated 225 
with significantly increased risk of death compared to those who had no recent chemotherapy use. However, 226 
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following correction for age and gender, patients with haematological malignancies who had recent chemotherapy 227 





Our results show that cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-231 
19 disease phenotypes, notably an association of increased SARS-CoV-2 hospital presentations in patients with 232 
haematological cancers. We have generated individualised risk tables for cancer patients displaying effect of 233 
age/sex and tumour subtype.  234 
 235 
There are variations and challenges in determining if COVID-19 was the direct cause of death for a patient, or if it 236 
was a terminal event in a patient who was approaching the end of their cancer care. All-causes case fatality rate 237 
was analysed in study and we feel this was a strength, in addition to the comparisons to a general cancer population 238 
control group.  239 
 240 
Patients with haematological malignancies (leukaemias, lymphomas and myelomas) are overrepresented, perhaps 241 
suggestive of an a priori increased viral susceptibility. Patients with extranodal NK/T-cell lymphoma-C86, 242 
Waldenström macroglobulinemia-C88, unspecified neoplasm of lymphoid, hematopoietic and related tissue-C96 243 
were greatly overrepresented. The reasons for this are unclear and likely reflects the small number of patients 244 
involved and stochastic effects (n=29), but it is possible that these haematological subtypes may have a specific 245 
immunological susceptibility to COVID-19 infection.  246 
 247 
Case fatality rate was compared relative to the median reference group, in order not to exaggerate the odds ratio 248 
and to take the most conservative approach. Patients with haematological malignancies were at greater risk of 249 
having a more severe COVID-19 clinical phenotype, to require more intensive supportive interventions, and to 250 
suffer an elevated risk of death. On multivariate analysis, patients with leukaemia still had a significantly higher risk 251 
of death related to COVID-19, considering age and gender. Admittedly, there are challenges in interpretation as 252 
this study relied on ICD-10 cancer subtype codes and leukaemia encompass a heterogeneous group of conditions. 253 
However, the increased case fatality rate in haematological malignancies is similar to that observed in a pre-print 254 
article from the United Kingdom 14 and Chinese cohorts 15 16, but in contrast to a recent American cohort study 17 255 
which does not suggest increased mortality in this group.  256 
 257 
Recent large COVID-19 cancer cohorts of predominantly solid organ tumours have identified no significant excess 258 
mortality risk from recent chemotherapy. 10 17 In this study, we have identified that in haematological malignancies, 259 
following multivariable analysis, risk does appear to be heightened by recent (within 4 weeks) or current 260 
chemotherapy, similar to that observed in other cohorts. 18 261 
 262 
There are likely to be a number of possible reasons for these observations. The immunological disruption per se 263 
observed in patients with leukaemia and the use of intensely myelosuppressive regimes may result in a devastating 264 
combination of risk, both in terms of the likelihood of initial SARS-CoV-2 infection, its ability to gain a foothold in 265 
the host and also in terms of the downstream disease course and likelihood of severe consequences such as 266 
cytokine storm and significant multiorgan failure. Further validation work is therefore important. 267 
 268 
Contrary to the findings from the Chinese series and data from a European registry 19, we found that patients with 269 
lung cancer were relatively underrepresented in the UKCCMP cohort compared to the ONS data. In addition, once 270 
COVID-19 was established in lung cancer patients, we found no significantly increased case fatality rate compared 271 
to the general COVID19+ cancer population within UKCCMP, suggesting that lung cancer patients are not a 272 
specifically vulnerable group. There are likely to be a number of reasons for this difference in findings. Firstly, there 273 
are methodological differences, with this study comparing lung cancer cases to a cancer population rather than a 274 
non-cancer population. Secondly, there may now be more effective shielding of lung cancer patients at an early 275 
stage in the pandemic when they were designated as clinically vulnerable. Thirdly, lung cancer is the commonest 276 
cancer in China, and hence would be overrepresented in their COVID-19+ cancer patient population and finally the 277 
European registry does not use a controlled group and this highlights the importance of our intra population-278 
controlled studies.  279 
 280 
Prostate cancer patients were relatively underrepresented in the UKCCMP cohort again compared to ONS data. 281 
In terms of risk of death once COVID-19 was established, initially the prostate cancer group of patients did appear 282 
to be an increased case fatality rate, but multivariate analysis showed that actually their risk was no greater than 283 
the rest of the COVID-19+ cancer population in UKCCMP, reflecting again the importance of age and gender more 284 




Patients with breast cancers or malignancies of the female genital tract appeared to be at much lower risk, either 287 
of contracting or of dying from COVID-19. However multivariate analysis again demonstrated that this protection 288 
was by virtue of the patients being female, rather than an inherently lower risk tumour per se.  289 
 290 
We accept some the limitations in our report. Our analyses are based on symptomatic cancer patients who seek 291 
help from cancer centres. Therefore, the cohort may not be entirely representative of all patients with cancer, and 292 
we observe a high proportion of patients with advanced/metastatic disease, patients who are under ongoing active 293 
oncological follow-up. It is also unlikely that patients on an end of life pathway or residing in nursing homes/hospices 294 
would be reported or included in this registry. There are potential limitations with the use of ONS control population 295 
of cancer patients as our comparator. In the presented study, we report on patients with current “active Cancer” 296 
whereas the ONS control population is a historical control, consisting of all patients with a diagnosis of cancer in 297 
2017 and it is possible that prognoses and therapeutic choices may have changed during this period. Therefore, it 298 
would be useful to perform analyses using more contemporaneous controls when these data become available. 299 
Other possible limitations include that performance status, patient co-morbidity scale/index and ethnicity were not 300 
initially collected as part of the study data entry form and therefore could not be used in multivariable models. 301 
However, rates of COVID-19 in cancer patients remain thankfully low overall and the age distribution of patients in 302 
the UKCCMP reflects the age distribution in the ONS dataset suggesting that our comparator population is as 303 
appropriate as possible at this stage.  304 
 305 
 In addition, as discussed, we observed a low admission rate of cancer patients to ITU, which is likely to impact on 306 
COVID-19 outcomes in cancer patients in the United Kingdom 10. Reasons for this low ITU admission rate, perhaps 307 
due to perceived futility of intensive support in cancer patients, warrants further exploration.  308 
 309 
Despite these limitations, our study is unique in comparing a large cancer COVID-19 population collected in real 310 
time to an accurate geographically appropriate cancer population control dataset. Morbidity and case fatality rate 311 
from COVID-19, once established, in UK cancer patients attending hospital is relatively high, particularly in those 312 
with haematological malignancies and advancing age, but we have established that not all cancer patients are 313 
affected equally, which is a very important finding, and will allow clinicians some ability to risk stratify their cancer 314 
populations and make informed decisions on appropriate levels of social isolation/shielding. Future work by the 315 
UKCCMP, in collaboration with international consortia will define risk in much greater granularity, including different 316 
subtypes of a given tumour.  317 
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  UKCCMP cases (%) ONS cases (%) Odds Ratio (95% CI) p value 
Patient Features         
-Male 595 (57.0%) 145034 (51.3%) 1.26 (1.12-1.43) 0.0002 
-Female 445 (42.6%) 137844 (48.7%)     
-Other 4 (0.4%) 0 (0.0%)     
-Median age/years 70 NA*     
Cancer Subtype         
-Breast (C50-C50) 143 (13.7%) 46109 (16.3%) 0.82 (0.68-0.98) 0.026 
-Colorectal (C18-C21) 124 (11.9%) 36039 (12.7%) 0.93 (0.76-1.12) 0.46 
-Prostate (C61) 114 (11.0%) 41200 (14.6%) 0.72 (0.59-0.88) 0.0008 
-Lung (C34) 111 (10.7%) 38878 (13.7%) 0.75 (0.61-0.91) 0.0033 
-Digestive organs (non-colorectal) (C15-C26) 95 (9.1%) 30096 (10.6%) 0.84 (0.68-1.04) 0.12 
-Urinary tract (C64-C68) 77 (7.4%) 19333 (6.8%) 1.09 (0.85-1.38) 0.46 
-Female genital organs (C51-C58) 56 (5.4%) 17969 (6.4%) 0.84 (0.63-1.10) 0.23 
-Lip, oral cavity and pharynx (C00-C14) 33 (3.2%) 7558 (2.7%) 1.19 (0.82-1.69) 0.33 
-Central nervous system (C69-C72) 25 (2.4%) 5038 (1.8%) 1.36 (0.87-2.02) 0.13 
-Mesothelial and soft tissue (C45-C49) 16 (1.5%) 4682 (1.7%) 0.93 (0.53-1.52) 0.90 
-Respiratory and intrathoracic organs (not lung) (C30-C39) 11 (1.1%) 2780 (1.0%) 1.08 (0.53-1.94) 0.75 
-Bone and articular cartilage (C40-C41) 4 (0.4%) 376 (0.1%) 2.90 (0.78-7.50) 0.053 
-Male genital organs (C60-C63) 4 (0.4%) 2435 (0.9%) 0.44 (0.12-1.14) 0.13 
-Endocrine glands (C73-C75) 4 (0.4%) 3374 (1.2%) 0.32 (0.09-0.82) 0.0096 
-Lymphoma (C81-C85) 79 (7.6%) 13537 (4.8%) 1.63 (1.28-2.06) <0.0001 
-Leukaemia (C91-C95) 79 (7.6%) 8018 (2.8%) 2.82 (2.21-3.55) <0.0001 
-Myeloma (C90) 37 (3.6%) 5033 (1.8%) 2.03 (1.42-2.83) 0.0001 
-Other Haematological (C86, C88, C96) 29 (2.8%) 423 (0.1%) 19.14 (12.59-28.05) <0.0001 
Table 1: Demographics and tumour subtype representation in the UKCCMP Covid-19 cohort compared to the ONS cancer control 318 
population. * Individual ages not available in dataset. Univariate analysis was performed, p values were determined by Fisher exact test 319 
and unadjusted for age and gender.  320 









ratio (95% CI) p value  
Multivariable 
adjusted odds 
ratio (95% CI) p value 
Prostate (C61) 49 0.43 2.14 (1.17-3.96) 0.014 1.09 (0.51-2.33) 0.82 
Lung (C34) 43 0.387 1.62 (0.89-3.00) 0.118 1.41 (0.75-2.67) 0.29 
Mesothelial and soft tissue (C45-C49) 6 0.375 1.18 (0.37-3.51) 0.772 1.52 (0.43-5.30) 0.51 
Urinary tract (C64-C68) 23 0.299 1.08 (0.54-2.13) 0.834 0.87 (0.41-1.81) 0.72 
Colorectal (C18-C21) 35 0.282 1.03 (0.56-1.90) 0.934 0.85 (0.44-1.64) 0.63 
Central nervous system (C69-C72) 7 0.28 1.15 (0.39-3.18) 0.797 1.87 (0.57-6.05) 0.29 
Respiratory organs (C30-C39) 3 0.273 0.84 (0.17-3.29) 0.813 0.96 (0.18-4.10) 0.95 
Lip, oral cavity and pharynx (C00-C14) 8 0.242 0.75 (0.28-1.85) 0.542 0.77 (0.25-2.27) 0.64 
Breast (C50) 26 0.182 0.53 (0.28-1.00) 0.049 0.97 (0.40-2.52) 0.94 
Female genital organs (C51-C58) 7 0.125 0.36 (0.13-0.87) 0.031 0.79 (0.24-2.63) 0.70 
Myeloma (C90) 16 0.432 1.85 (0.81-4.22) 0.142 1.65 (0.71-3.85) 0.24 
Leukaemia (C91-C95) 33 0.418 2.03 (1.04-3.97) 0.038 2.25 (1.13-4.57) 0.02 
Lymphoma (C81-C85) 25 0.316 1.60 (0.80-3.19) 0.184 1.72 (0.81-3.68) 0.16 
Other Haematological (C86, C88, C96) 7 0.241 0.81 (0.28-2.12) 0.675 0.81 (0.26-2.33) 0.70 
Digestive organs (C15-C17, C22-C26) 28 0.295 Reference Reference Reference Reference 
 322 
Table 2: All-cause case fatality rate following COVID-19 by tumour subtype, before and after age and sex correction. Odds ratio was 323 
performed relative to Digestive organs (non-colorectal) (C15-C26). Multivariable corrections were performed correcting for patient age 324 











Figure 2: Heatmap demonstrating case fatality rate following a COVID-19 presentation, broken down by tumour subtype, age and 334 
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Research in Context 413 
 414 
Evidence before the study:  415 
A literature review was performed using PubMed for all studies from 1st December 2019 to 1st July 2020 related to 416 
SARS-CoV-2 infection susceptibility and clinical course of coronavirus disease (COVID-19) in cancer patients. This 417 
used the search terms, COVID-19, SARS-CoV-2, cancer and was not limited to English language publications. 418 
Several studies describe the correlations of patient demographics, namely age and gender and increased COVID-419 
19 morbidity and mortality including Docherty et al (2020), Robilotti et al (2020), Miyashita et al (2020). Two pivotal 420 
cancer cohorts have identified no significant effect of chemotherapy on mortality, Lee et al (2020), Kuderer et al 421 
(2020) and this was also noted by Vaugnat et al (2020). However, a small study had identified a small risk, Yang 422 
et al (2020). The effect of cancer subtype is unclear. Dai et al (2020) identified that patients with haematological or 423 
lung malignancies have a poorer disease course. The elevated risk in haematological malignancies was also noted 424 
by Yang et al (2020) and in lung cancer by Garassino et al (2020), but Kuderer et al (2020) did not identify increased 425 
mortality by cancer subtype.  426 
 427 
Added value of the study 428 
This UK Coronavirus Cancer Monitoring Project (UKCCMP) study is a national monitoring project of cancer patients 429 
who contract COVID-19 disease, consisting of 1044 patients to date. We have compared cancer patients enrolled 430 
in the UKCCMP and a parallel non-COVID-19 UK cancer control population cohort, analysing the effect of tumour 431 
features (primary subtype and stage) and patient demographics (age and sex) on the risk and the trajectory of 432 
COVID-19 disease. Tumour features (primary subtype and stage) as well as patient demographics impact on viral 433 
susceptibility and COVID-19 disease phenotype. There is increased SARS-CoV-2 susceptibility in patients with 434 
haematological cancers (leukaemia/lymphoma/myeloma). Haematology patients run a more severe COVID-19 435 
disease trajectory and require more intensive clinical support with additional risk conferred by recent chemotherapy 436 
use.  As observed in the general population, age and gender are predominant risk factors for SARS-CoV-2 infection 437 
and severity of COVID-19 disease for most cancer patients.  438 
 439 
Implications of all the available evidence 440 
Our data indicates that cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-441 
19 disease phenotypes, notably association of increased SARS-CoV-2 susceptibility in patients with 442 
haematological cancers. We have generated individualised risk tables for cancer patients taking into account 443 
age/sex and tumour subtype. This will be useful for physicians to have a more informed risk-benefit discussion to 444 
explain COVID-19 risk to their cancer patients. 445 
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Patients with a diagnosis of cancer are purported to have poor outcomes from COVID-19. However, cancer is a 51 
heterogeneous group of diseases encompassing a spectrum of tumour subtypes. The aim of this study is to 52 
evaluate COVID-19 risk according to tumour subtype and patient demographics in the cancer population. 53 
 54 
Methods 55 
A comparison of adult cancer patients enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) from 56 
18th March to 8th May and a parallel non-COVID-19 UK cancer control population cohort was performed, analysing 57 
effect of tumour subtype and patient demographics (age and sex) on the incidence and mortality from COVID-19 58 
using univariate and multivariable models. 59 
   60 
Findings 61 
In 1,044 patients with COVID-19, an overall case fatality rate of 0.31 was observed, of which 92.5% (295/319) of 62 
deaths due to COVID-19. Age is a risk factor for COVID-19 with a case fatality rate (CFR) in the 40-49, 50-59, 60-63 
69, 70-79 and over 80 groups being 0.10, 0.17, 0.28, 0.35 and 0.48 respectively. Patients with haematological 64 
malignancies (leukaemia/lymphoma/myeloma) run a more severe COVID-19 trajectory (OR 1.57, 95% CI 1.15-65 
2.15; p<0.01) compared to patients with solid organ tumours.  CFR following COVID-19 in patients with leukaemia 66 
is increased compared to other cancer types, even considering other risk factors (OR 2.25, 95% CI [1.13 to 4.57]; 67 
p=0.02). Recent chemotherapy use in haematological patients is associated with additional risk of death on 68 
multivariate analyses (OR 2.09 95% CI [1.09 to 4.08]; p=0.03). 69 
 70 
Interpretation 71 
Cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-19 phenotypes. We 72 
have generated individualised risk tables for cancer patients taking into account age/sex and tumour subtype. This 73 
will be useful for physicians to have an informed risk-benefit discussion to explain COVID-19 risk and to enable an 74 
evidenced approach to national social isolation policies.  75 
 76 
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The disease course of individuals contracting SARS-CoV-2 infection is phenotypically diverse. Many patients suffer 81 
only mild symptoms and it is becoming increasingly apparent from antibody data that others suffer no symptoms 82 
at all but can actively carry and transmit the infection. However, at the other end of the spectrum, some individuals 83 
develop very severe symptoms and can follow an extreme phenotype with the development of respiratory failure, 84 
cytokine release syndrome and multi-organ failure. Subgroups of COVID-19 patients have been identified who 85 
appear to be at increased risk of morbidity and mortality, including patients of advancing age, male gender (versus 86 
female) and those with co-morbidities such as hypertension, chronic lung disease, diabetes and cancer. 1 87 
 88 
Since COVID-19 started to spread across the globe in early 2020, patients with a diagnosis of cancer were 89 
designated as a particularly vulnerable subgroup of the population. Cancer patients have been reported to be not 90 
only at increased risk of contracting SARS-CoV-2 infections, but also of running a more severe disease course, 91 
with a large proportion requiring higher levels of intensive care, having a more rapidly evolving disease, and with 92 
increased risk of death. 2 3 4  However, cancer encompasses a myriad of disease, with a diverse array of primary 93 
tumour subtype and stages, affecting a heterogeneous group of patients of all ages, and which result in very 94 
different cancer prognoses and outcomes. Therefore, labelling all cancer patients as ‘COVID-19 vulnerable’ is 95 
probably neither reasonable nor informative.  96 
 97 
As a consequence of generic advice given to ‘COVID-19 clinically vulnerable’ members of the population, cancer 98 
patients (of any age, gender, tumour subtype and stage) have been labelled as high risk from COVID-19 and this 99 
has led to sweeping changes in cancer management for all cancer types over the last few months, including 100 
abbreviation of radiotherapy, switching from IV to oral chemotherapy regimens, and modification in immunotherapy 101 
usage. 5 6 7 8 These changes, perhaps reasonably in an acute pandemic situation, were instigated with very little 102 
evidence to support them. Due to a paucity of evidence, there has been little attempt to define the individualised 103 
risk for a given patient, taking into account their primary tumour subtype, age and gender. 104 
 105 
We report here, from the UK Coronavirus Cancer Monitoring Project 9, the first analysis of the complex interaction 106 
between patient demographics and tumour subtype, to more accurately estimate the risk of SARS-CoV-2 infection 107 
/ COVID-19 in patients with cancer. We describe the clinical outcomes of COVID-19+ cancer patients entered on 108 
the UKCCMP registry, and compare primary cancer subtype prevalence/case fatality rate to the United Kingdom’s 109 





Study Design and Participants 113 
The UK Coronavirus Cancer Monitoring Project (UKCCMP) database of United Kingdom (UK) cancer patients has 114 
been designed as a Public Health Surveillance registry for the COVID-19 pandemic and a prospective 115 
observational cohort study 10. The database was designed as a public health surveillance registry to support rapid 116 
clinical decision making, in accordance with the UK Policy Framework for Health and Social Care Research, the 117 
UK National Research Ethics Service, and the UK Governance Arrangement for Research Ethic Committees.  118 
Ethical approval was not specifically required, as confirmed following consultation with the Health Research 119 
Authority (HRA). The study involved the collection of clinical and outcome data as routinely recommended for good 120 
practice. Each participating centre was required to obtain local approvals and follow local information governance 121 
processes. Written consent was not required for inclusion in this study. Eligibility criteria were (1)  adult patients 122 
(18 and older), (2) with active cancer, (3) who presented to the UKCCMP network from March 18th 2020 to 8th May 123 
2020, (4) with a positive SARS-CoV-2 PCR test were eligible for enrolment on the registry. Patients with active 124 
cancer were defined as those with metastatic cancer or those undergoing anti-cancer treatment in any setting 125 
(curative/radical/adjuvant/neoadjuvant) or those treated within the past 12 months with surgery/systemic anti-126 
cancer therapy/radiotherapy. All patients attended secondary care to be reviewed for potential hospitalization and 127 
were not part of a proactive surveillance program. Management of cancer patients with COVID-19 was directed by 128 
the patient’s clinician team without input from the UKCCMP and were based on local policies and standard UK 129 
clinical practice at the time of this study. Decisions on ITU admission and ventilation were guided by the UK National 130 
Health Service, National Institute of Health and Care Excellence COVID-19 rapid guidelines. 11 This study was 131 
conducted in accordance with the Strengthening the Reporting of Observational studies in Epidemiology 132 
(STROBE) statement.  133 
 134 
Data Collection and analysis 135 
Data collection was performed as previously outlined 10. Tumour subtype and demographics analysis utilised the 136 
latest release of the “Cancer Registration Statistics, England, 2017” 12. This is the latest cancer registration 137 
database in England and involves registrations of patients up to 2017. Cancer registrations in England take years 138 
after a given calendar year to reach nationally validated quality control measures for robustness of analyses due 139 
to continuing accrual of registrations.  140 
 141 
Outcomes 142 
The main outcome of interest was the effect of primary tumour subtype, age and gender, and likelihood of 143 
contracting SARS-CoV-2 infection and subsequent COVID-19 clinical course. A comparison of adult cancer 144 
patients enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) and a parallel non-COVID-19 UK 145 
cancer control population cohort was performed (the UK Office for National Statistics (ONS) cancer control 146 
dataset), analysing effect of tumour subtype and patient demographics (age and sex) on the incidence and mortality 147 
from COVID-19 using univariate fisher exact tests and multivariable logistic regression. The primary outcome of 148 
interest was all-cause inpatient case fatality rate (during the COVID-19 episode). This included death designated 149 
as a direct result of COVID-19 as well as death from any other cause such as cancer progression and treatment 150 
toxicity. Skin cancers were not included in these analyses as the majority are not managed in oncological setting 151 
so they are not representative as a comparison group.  152 
 153 
Statistical analysis & Data visualisation 154 
 155 
This analysis was a pre-planned analysis milestone. Analyses were performed without an a priori power calculation, 156 
as this were not possible due to the lack of information about the effect size/interactions and the nature and rapid 157 
evolution of the pandemic. Patients that had missing data points required for a particular analysis were excluded. 158 
A two-sided Fisher’s exact test was used to compare categorical data from different categories. Multivariable 159 
logistic regression 13 was used to estimate odds ratios and 95% confidence intervals of each defined factor after 160 
adjustment for potential confounders of patient age and gender. Analyses were performed in R version 3.6.3. 161 
 162 
Role of the funding source 163 
 164 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of 165 
the report. LL, JBC, TS, RA, VB, NAC, HMC, AS, SH, CPM, CP, ASO, CDT, CV had access to the raw data. LL, 166 





We are reporting on 1,044 patients with active cancer and a documented SARS-CoV-2 infection/COVID-19 170 
registered in the UKCCMP database from the 18th of March with outcomes censored at 8th May 2020. 87 patients 171 
were excluded from the analysis as they had an unspecified tumour site or malignant neoplasia of the skin. Of this 172 
cohort, 595/1044 were men (57.0%) and the median age was 70 years, IQR 60-77. Patients were followed up from 173 
the point of COVID-19 diagnosis to either discharge from hospital or death. Median follow up was 6 days (IQR 2-174 
11). 175 
 176 
The demographics and cancer subtype of the COVID-19+ cancer population from the UKCCMP registry were 177 
compared with those from the population of cancer patients represented in the ONS cancer census which was 178 
used as a historical control group. Compared to the ONS control population of cancer patients, we found that 179 
COVID-19+ cancer patients were significantly more likely to be male (57.1% (592/1037) in UKCCMP vs 51.3% 180 
(145034/282878) in ONS, OR 1.26 95% CI [1.12 to 1.43]; p<0.01), but the age distribution of cancer patients who 181 
contracted COVID-19 was not significantly different to the ONS cancer control population (median age group 70-182 
79 for both series) (appendix page 2).  183 
 184 
We found that certain tumour subtypes were overrepresented in the UKCCMP COVID-19+ patient cohort compared 185 
with the ONS control population. Patients with haematological malignancies appeared to be at significantly 186 
increased risk, and these included those with leukaemia (OR 2.82 95% CI [2.21 to 3.55]; p<0.01), myeloma (OR 187 
2.03 95% CI [1.42 to 2.83]; p<0.01) and lymphomas (OR 1.63 95% CI [1.28 to 2.06]; p<0.01) (Table 1). In contrast, 188 
patients with lung cancer and prostate cancer were relatively underrepresented in the COVID19+ UKCCMP series 189 
compared to the control ONS series of cancers. Lung cancer made up 10.7% (111/1041) of the UKCCMP series 190 
compared to 13.7% (38878/282878) of ONS cases (OR 0.75 95%CI [0.61-0.91]; p<0.01). Similarly, prostate cancer 191 
comprised 11.0% (114/1041) of the UKCCMP series compared to 14.6% (41200/282878) of the ONS cohort (OR 192 
0.72 95%CI [0.59-0.88]; p<0.01). 193 
 194 
319 of the 1044 COVID-19+ UKCCMP cancer patients died, a case fatality rate (CFR) 0.31, of which the cause of 195 
death was recorded as due to COVID-19 in 92.5% (n=295). The all-cause CFR in cancer patients following COVID-196 
19 was significantly linked to increasing age, with the CFR in the 40-49, 50-59, 60-69, 70-79 and over 80 groups 197 
being 0.10, 0.17, 0.28, 0.35 and 0.48 respectively, and no deaths recorded in the under 40 group (Figure 1, 198 
Appendix page 2-3). In addition, the all-cause CFR in cancer patients once they had contracted COVID-19 was 199 
significantly associated with gender, in males being 0.36 (212/595) and that in females being 0.24 (105/445), (OR 200 
1.92 95% CI [1.51 to 2.45], p<0.01)   201 
 202 
We compared the case fatality rate for each primary tumour subtype in the UKCCMP to a reference, the C15-C26 203 
subtype (digestive organs) as it was the tumour subtype with the central case fatality rate. On univariate analysis 204 
we observed a significantly higher risk in patients with prostate cancer (OR 2.14, 95% CI [1.17 to 3.96]; p=0.01), 205 
and leukaemia (OR 2.03, 95% CI [1.04 to 3.97]; p=0.04) and a significantly lower risk for patients with breast cancer 206 
(OR 0.53, 95% CI [0.28 to 1.00]; p<0.05) and female genital cancers (OR 0.36, 95% CI [0.13-0.87]; p=0.03) (Figure 207 
2, appendix page 3). We then performed a multivariate correction for clinically relevant confounders, age and 208 
gender. Compared to the rest of the UKCCMP cohort, patients with leukaemia remained at significantly increased 209 
case fatality rate (OR 2.25, 95% CI [1.13 to 4.57]; p=0.02),  (Table 2, appendix page 4). After multivariate correction, 210 
prostate cancer was no longer significantly associated with increased case fatality rate, and breast and female 211 
genital cancers were no longer associated with reduced case fatality rate, highlighting the striking effect of patient 212 
age and gender on case fatality rate. Also, on multivariate analysis, we did not find a significantly increased case 213 
fatality rate from COVID-19 in the lung cancer population (OR 1.41 95%CI [0.75-2.67]; p=0.29) compared to the 214 
rest of the UKCCMP population. 215 
 216 
We then undertook a specific detailed analysis of the 227 patients with haematological malignancies who were 217 
diagnosed with COVID-19. Compared to the remainder of the UKCCMP cohort (with non-haematological cancers), 218 
we found that these patients presented with similar symptoms (appendix page 5). Adjusting for potential 219 
confounding variables of age and gender, patients with haematological malignancies were significantly more likely 220 
to require high flow oxygen (OR 1.82 95% CI [1.11 to 2.94]; p =0.015)], non-invasive ventilation (OR 2.10 95% CI 221 
[1.14-3.76; p=0.01]), ITU admission for ventilation (OR 2.73 % CI [1.43 to 5.11]; p<0.01) and have a severe/critical 222 
disease course (OR 1.57 95% CI [1.15 to 2.15]; p<0.01) (appendix page 5). 47.6% (108/227) of patients with 223 
haematological malignancies had received recent chemotherapy within 4 weeks of COVID-19 presentation 224 
(appendix page 5). On univariate analysis, recent use of chemotherapy in haematology patients was not associated 225 
with significantly increased risk of death compared to those who had no recent chemotherapy use. However, 226 
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following correction for age and gender, patients with haematological malignancies who had recent chemotherapy 227 





Our results show that cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-231 
19 disease phenotypes, notably an association of increased SARS-CoV-2 hospital presentations in patients with 232 
haematological cancers. We have generated individualised risk tables for cancer patients displaying effect of 233 
age/sex and tumour subtype.  234 
 235 
There are variations and challenges in determining if COVID-19 was the direct cause of death for a patient, or if it 236 
was a terminal event in a patient who was approaching the end of their cancer care. All-causes case fatality rate 237 
was analysed in study and we feel this was a strength, in addition to the comparisons to a general cancer population 238 
control group.  239 
 240 
Patients with haematological malignancies (leukaemias, lymphomas and myelomas) are overrepresented, perhaps 241 
suggestive of an a priori increased viral susceptibility. Patients with extranodal NK/T-cell lymphoma-C86, 242 
Waldenström macroglobulinemia-C88, unspecified neoplasm of lymphoid, hematopoietic and related tissue-C96 243 
were greatly overrepresented. The reasons for this are unclear and likely reflects the small number of patients 244 
involved and stochastic effects (n=29), but it is possible that these haematological subtypes may have a specific 245 
immunological susceptibility to COVID-19 infection.  246 
 247 
Case fatality rate was compared relative to the median reference group, in order not to exaggerate the odds ratio 248 
and to take the most conservative approach. Patients with haematological malignancies were at greater risk of 249 
having a more severe COVID-19 clinical phenotype, to require more intensive supportive interventions, and to 250 
suffer an elevated risk of death. On multivariate analysis, patients with leukaemia still had a significantly higher risk 251 
of death related to COVID-19, considering age and gender. Admittedly, there are challenges in interpretation as 252 
this study relied on ICD-10 cancer subtype codes and leukaemia encompass a heterogeneous group of conditions. 253 
However, the increased case fatality rate in haematological malignancies is similar to that observed in a pre-print 254 
article from the United Kingdom 14 and Chinese cohorts 15 16, but in contrast to a recent American cohort study 17 255 
which does not suggest increased mortality in this group.  256 
 257 
Recent large COVID-19 cancer cohorts of predominantly solid organ tumours have identified no significant excess 258 
mortality risk from recent chemotherapy. 10 17 In this study, we have identified that in haematological malignancies, 259 
following multivariable analysis, risk does appear to be heightened by recent (within 4 weeks) or current 260 
chemotherapy, similar to that observed in other cohorts. 18 261 
 262 
There are likely to be a number of possible reasons for these observations. The immunological disruption per se 263 
observed in patients with leukaemia and the use of intensely myelosuppressive regimes may result in a devastating 264 
combination of risk, both in terms of the likelihood of initial SARS-CoV-2 infection, its ability to gain a foothold in 265 
the host and also in terms of the downstream disease course and likelihood of severe consequences such as 266 
cytokine storm and significant multiorgan failure. Further validation work is therefore important. 267 
 268 
Contrary to the findings from the Chinese series and data from a European registry 19, we found that patients with 269 
lung cancer were relatively underrepresented in the UKCCMP cohort compared to the ONS data. In addition, once 270 
COVID-19 was established in lung cancer patients, we found no significantly increased case fatality rate compared 271 
to the general COVID19+ cancer population within UKCCMP, suggesting that lung cancer patients are not a 272 
specifically vulnerable group. There are likely to be a number of reasons for this difference in findings. Firstly, there 273 
are methodological differences, with this study comparing lung cancer cases to a cancer population rather than a 274 
non-cancer population. Secondly, there may now be more effective shielding of lung cancer patients at an early 275 
stage in the pandemic when they were designated as clinically vulnerable. Thirdly, lung cancer is the commonest 276 
cancer in China, and hence would be overrepresented in their COVID-19+ cancer patient population and finally the 277 
European registry does not use a controlled group and this highlights the importance of our intra population-278 
controlled studies.  279 
 280 
Prostate cancer patients were relatively underrepresented in the UKCCMP cohort again compared to ONS data. 281 
In terms of risk of death once COVID-19 was established, initially the prostate cancer group of patients did appear 282 
to be an increased case fatality rate, but multivariate analysis showed that actually their risk was no greater than 283 
the rest of the COVID-19+ cancer population in UKCCMP, reflecting again the importance of age and gender more 284 




Patients with breast cancers or malignancies of the female genital tract appeared to be at much lower risk, either 287 
of contracting or of dying from COVID-19. However multivariate analysis again demonstrated that this protection 288 
was by virtue of the patients being female, rather than an inherently lower risk tumour per se.  289 
 290 
We accept some the limitations in our report. Our analyses are based on symptomatic cancer patients who seek 291 
help from cancer centres. Therefore, the cohort may not be entirely representative of all patients with cancer, and 292 
we observe a high proportion of patients with advanced/metastatic disease, patients who are under ongoing active 293 
oncological follow-up. It is also unlikely that patients on an end of life pathway or residing in nursing homes/hospices 294 
would be reported or included in this registry. There are potential limitations with the use of ONS control population 295 
of cancer patients as our comparator. In the presented study, we report on patients with current “active Cancer” 296 
whereas the ONS control population is a historical control, consisting of all patients with a diagnosis of cancer in 297 
2017 and it is possible that prognoses and therapeutic choices may have changed during this period. Therefore, it 298 
would be useful to perform analyses using more contemporaneous controls when these data become available. 299 
Other possible limitations include that performance status, patient co-morbidity scale/index and ethnicity were not 300 
initially collected as part of the study data entry form and therefore could not be used in multivariable models. 301 
However, rates of COVID-19 in cancer patients remain thankfully low overall and the age distribution of patients in 302 
the UKCCMP reflects the age distribution in the ONS dataset suggesting that our comparator population is as 303 
appropriate as possible at this stage.  304 
 305 
 In addition, as discussed, we observed a low admission rate of cancer patients to ITU, which is likely to impact on 306 
COVID-19 outcomes in cancer patients in the United Kingdom 10. Reasons for this low ITU admission rate, perhaps 307 
due to perceived futility of intensive support in cancer patients, warrants further exploration.  308 
 309 
Despite these limitations, our study is unique in comparing a large cancer COVID-19 population collected in real 310 
time to an accurate geographically appropriate cancer population control dataset. Morbidity and case fatality rate 311 
from COVID-19, once established, in UK cancer patients attending hospital is relatively high, particularly in those 312 
with haematological malignancies and advancing age, but we have established that not all cancer patients are 313 
affected equally, which is a very important finding, and will allow clinicians some ability to risk stratify their cancer 314 
populations and make informed decisions on appropriate levels of social isolation/shielding. Future work by the 315 
UKCCMP, in collaboration with international consortia will define risk in much greater granularity, including different 316 
subtypes of a given tumour.  317 
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  UKCCMP cases (%) ONS cases (%) Odds Ratio (95% CI) p value 
Patient Features         
-Male 595 (57.0%) 145034 (51.3%) 1.26 (1.12-1.43) 0.0002 
-Female 445 (42.6%) 137844 (48.7%)     
-Other 4 (0.4%) 0 (0.0%)     
-Median age/years 70 NA*     
Cancer Subtype         
-Breast (C50-C50) 143 (13.7%) 46109 (16.3%) 0.82 (0.68-0.98) 0.026 
-Colorectal (C18-C21) 124 (11.9%) 36039 (12.7%) 0.93 (0.76-1.12) 0.46 
-Prostate (C61) 114 (11.0%) 41200 (14.6%) 0.72 (0.59-0.88) 0.0008 
-Lung (C34) 111 (10.7%) 38878 (13.7%) 0.75 (0.61-0.91) 0.0033 
-Digestive organs (non-colorectal) (C15-C26) 95 (9.1%) 30096 (10.6%) 0.84 (0.68-1.04) 0.12 
-Urinary tract (C64-C68) 77 (7.4%) 19333 (6.8%) 1.09 (0.85-1.38) 0.46 
-Female genital organs (C51-C58) 56 (5.4%) 17969 (6.4%) 0.84 (0.63-1.10) 0.23 
-Lip, oral cavity and pharynx (C00-C14) 33 (3.2%) 7558 (2.7%) 1.19 (0.82-1.69) 0.33 
-Central nervous system (C69-C72) 25 (2.4%) 5038 (1.8%) 1.36 (0.87-2.02) 0.13 
-Mesothelial and soft tissue (C45-C49) 16 (1.5%) 4682 (1.7%) 0.93 (0.53-1.52) 0.90 
-Respiratory and intrathoracic organs (not lung) (C30-C39) 11 (1.1%) 2780 (1.0%) 1.08 (0.53-1.94) 0.75 
-Bone and articular cartilage (C40-C41) 4 (0.4%) 376 (0.1%) 2.90 (0.78-7.50) 0.053 
-Male genital organs (C60-C63) 4 (0.4%) 2435 (0.9%) 0.44 (0.12-1.14) 0.13 
-Endocrine glands (C73-C75) 4 (0.4%) 3374 (1.2%) 0.32 (0.09-0.82) 0.0096 
-Lymphoma (C81-C85) 79 (7.6%) 13537 (4.8%) 1.63 (1.28-2.06) <0.0001 
-Leukaemia (C91-C95) 79 (7.6%) 8018 (2.8%) 2.82 (2.21-3.55) <0.0001 
-Myeloma (C90) 37 (3.6%) 5033 (1.8%) 2.03 (1.42-2.83) 0.0001 
-Other Haematological (C86, C88, C96) 29 (2.8%) 423 (0.1%) 19.14 (12.59-28.05) <0.0001 
Table 1: Demographics and tumour subtype representation in the UKCCMP Covid-19 cohort compared to the ONS cancer control 318 
population. * Individual ages not available in dataset. Univariate analysis was performed, p values were determined by Fisher exact test 319 
and unadjusted for age and gender.  320 









ratio (95% CI) p value  
Multivariable 
adjusted odds 
ratio (95% CI) p value 
Prostate (C61) 49 0.43 2.14 (1.17-3.96) 0.014 1.09 (0.51-2.33) 0.82 
Lung (C34) 43 0.387 1.62 (0.89-3.00) 0.118 1.41 (0.75-2.67) 0.29 
Mesothelial and soft tissue (C45-C49) 6 0.375 1.18 (0.37-3.51) 0.772 1.52 (0.43-5.30) 0.51 
Urinary tract (C64-C68) 23 0.299 1.08 (0.54-2.13) 0.834 0.87 (0.41-1.81) 0.72 
Colorectal (C18-C21) 35 0.282 1.03 (0.56-1.90) 0.934 0.85 (0.44-1.64) 0.63 
Central nervous system (C69-C72) 7 0.28 1.15 (0.39-3.18) 0.797 1.87 (0.57-6.05) 0.29 
Respiratory organs (C30-C39) 3 0.273 0.84 (0.17-3.29) 0.813 0.96 (0.18-4.10) 0.95 
Lip, oral cavity and pharynx (C00-C14) 8 0.242 0.75 (0.28-1.85) 0.542 0.77 (0.25-2.27) 0.64 
Breast (C50) 26 0.182 0.53 (0.28-1.00) 0.049 0.97 (0.40-2.52) 0.94 
Female genital organs (C51-C58) 7 0.125 0.36 (0.13-0.87) 0.031 0.79 (0.24-2.63) 0.70 
Myeloma (C90) 16 0.432 1.85 (0.81-4.22) 0.142 1.65 (0.71-3.85) 0.24 
Leukaemia (C91-C95) 33 0.418 2.03 (1.04-3.97) 0.038 2.25 (1.13-4.57) 0.02 
Lymphoma (C81-C85) 25 0.316 1.60 (0.80-3.19) 0.184 1.72 (0.81-3.68) 0.16 
Other Haematological (C86, C88, C96) 7 0.241 0.81 (0.28-2.12) 0.675 0.81 (0.26-2.33) 0.70 
Digestive organs (C15-C17, C22-C26) 28 0.295 Reference Reference Reference Reference 
 322 
Table 2: All-cause case fatality rate following COVID-19 by tumour subtype, before and after age and sex correction. Odds ratio was 323 
performed relative to Digestive organs (non-colorectal) (C15-C26). Multivariable corrections were performed correcting for patient age 324 











Figure 2: Heatmap demonstrating case fatality rate following a COVID-19 presentation, broken down by tumour subtype, age and 334 
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Research in Context 413 
 414 
Evidence before the study:  415 
A literature review was performed using PubMed for all studies from 1st December 2019 to 1st July 2020 related to 416 
SARS-CoV-2 infection susceptibility and clinical course of coronavirus disease (COVID-19) in cancer patients. This 417 
used the search terms, COVID-19, SARS-CoV-2, cancer and was not limited to English language publications. 418 
Several studies describe the correlations of patient demographics, namely age and gender and increased COVID-419 
19 morbidity and mortality including Docherty et al (2020), Robilotti et al (2020), Miyashita et al (2020). Two pivotal 420 
cancer cohorts have identified no significant effect of chemotherapy on mortality, Lee et al (2020), Kuderer et al 421 
(2020) and this was also noted by Vaugnat et al (2020). However, a small study had identified a small risk, Yang 422 
et al (2020). The effect of cancer subtype is unclear. Dai et al (2020) identified that patients with haematological or 423 
lung malignancies have a poorer disease course. The elevated risk in haematological malignancies was also noted 424 
by Yang et al (2020) and in lung cancer by Garassino et al (2020), but Kuderer et al (2020) did not identify increased 425 
mortality by cancer subtype.  426 
 427 
Added value of the study 428 
This UK Coronavirus Cancer Monitoring Project (UKCCMP) study is a national monitoring project of cancer patients 429 
who contract COVID-19 disease, consisting of 1044 patients to date. We have compared cancer patients enrolled 430 
in the UKCCMP and a parallel non-COVID-19 UK cancer control population cohort, analysing the effect of tumour 431 
features (primary subtype and stage) and patient demographics (age and sex) on the risk and the trajectory of 432 
COVID-19 disease. Tumour features (primary subtype and stage) as well as patient demographics impact on viral 433 
susceptibility and COVID-19 disease phenotype. There is increased SARS-CoV-2 susceptibility in patients with 434 
haematological cancers (leukaemia/lymphoma/myeloma). Haematology patients run a more severe COVID-19 435 
disease trajectory and require more intensive clinical support with additional risk conferred by recent chemotherapy 436 
use.  As observed in the general population, age and gender are predominant risk factors for SARS-CoV-2 infection 437 
and severity of COVID-19 disease for most cancer patients.  438 
 439 
Implications of all the available evidence 440 
Our data indicates that cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-441 
19 disease phenotypes, notably association of increased SARS-CoV-2 susceptibility in patients with 442 
haematological cancers. We have generated individualised risk tables for cancer patients taking into account 443 
age/sex and tumour subtype. This will be useful for physicians to have a more informed risk-benefit discussion to 444 
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